FIELD: medicine; pharmaceuticals.
SUBSTANCE: pharmaceutical combination comprising (a) CDK4/6 inhibitor, (b) a B-Raf inhibitor, and optionally (c) a MEK 1/2 inhibitor; combined preparations and pharmaceutical compositions thereof; use of such a combination in the treatment of proliferative diseases; methods of treating subjects suffering from proliferative diseases comprising administering a therapeutically effective amount of such combination.
EFFECT: treatment of proliferative diseases.
10 cl, 4 ex, 1 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| COMBINATION THERAPY | 2018 |
|
RU2815400C2 |
| THERAPEUTIC COMBINATIONS CONTAINING RAF INHIBITOR AND ERK INHIBITOR | 2017 |
|
RU2774612C2 |
| SYNERGISTIC COMBINATIONS OF PI3K- AND MEK-INHIBITORS | 2012 |
|
RU2607944C2 |
| COMBINATION OF (A) PHOSPHOINOSITIDE-3-KINASE INHIBITOR AND (B) Ras/Raf/Mek PATHAWAY MODULATOR | 2009 |
|
RU2508110C2 |
| COMBINATIONS OF PI3K INHIBITOR AND MEK INHIBITOR | 2010 |
|
RU2563193C2 |
| PHARMACEUTICAL COMBINATIONS | 2017 |
|
RU2759669C2 |
| PHARMACEUTICAL COMBINATIONS | 2013 |
|
RU2674995C2 |
| COMBINATION THERAPY FOR CANCER TREATMENT | 2014 |
|
RU2805145C2 |
| COMBINATION THERAPY FOR TREATMENT OF CANCER | 2014 |
|
RU2680714C2 |
| COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | 2006 |
|
RU2387653C2 |
